Anlotinib plus an injection after esophageal cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests whether anlotinib tablets combined with an injection (TQB2450) can lower the risk of esophageal squamous cell cancer coming back after surgery. It may help by targeting cancer growth signals and blood-vessel formation to reduce recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older, and be able to follow study instructions and return for follow-ups
- Have esophageal squamous cell carcinoma that fits a specific post-surgery stage pattern (T1–4, with N1–3 and M0)
- Have had curative surgery with complete tumor removal (R0) and no recurrence on scans 6–12 weeks after surgery
- Need an additional (adjuvant) treatment after surgery, as judged by the study team
- Have blood counts and organ tests within required ranges (kidneys, liver, clotting) and heart strength with LVEF above 50%
- Not have had other cancer drug treatments after surgery, and not have had prior immune therapy or anti-VEGF/VEGFR targeted therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy and a drug called anlotinib (which helps stop blood vessel growth to tumors) after surgery for esophageal cancer. If you had some cancer left after surgery and it spread to lymph nodes, this treatment might help prevent the cancer from coming back.
This trial tests a combination of drugs (anlotinib, immunotherapy, and chemotherapy) given before surgery for esophageal cancer that has not spread to other organs. The goal is to see if this approach shrinks the tumor and improves outcomes.
This Phase 2 trial tests penpulimab plus chemotherapy (with or without an added targeted pill called anlotinib) in people with advanced esophageal squamous cell carcinoma. It aims to slow tumor growth and improve outcomes, especially for patients who can’t have curative surgery or radiation.
This trial tests a new combination of two drugs, anlotinib and benmelstobart, for people with advanced esophageal squamous cell carcinoma that has not been treated before or has come back after more than six months. The goal is to see if this combination can help control the cancer and improve outcomes.
This Phase 2 trial tests TQB2450 (a new cancer medicine) added to chemotherapy, or along with an oral medicine called anlotinib, for stage II–IIIB non-small cell lung cancer. It may help shrink tumors and improve outcomes in people who are getting curative surgery and have not had prior cancer drug treatment.
This trial tests if anlotinib (a targeted therapy) can help prevent lung cancer from returning after surgery for patients whose tumors did not completely disappear after chemotherapy plus immunotherapy before surgery.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.